• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利：CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法，用中文像聊天一样搜索，搜遍4000万医学文献。AI智能推荐，让科研检索更轻松。

立即免费搜索

文件翻译

保留排版，准确专业，支持PDF/Word/PPT等文件格式，支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述，25分钟生成高质量综述，智能提取关键信息，辅助科研写作。

立即免费体验

相似文献

1
Buprenorphine Treatment: Advanced Practice Nurses Add Capacity.丁丙诺啡治疗：高级执业护士增加服务能力。
Health Aff (Millwood). 2022 Sep;41(9):1231-1237. doi: 10.1377/hlthaff.2022.00310.
2
Changes in US Clinician Waivers to Prescribe Buprenorphine Management for Opioid Use Disorder During the COVID-19 Pandemic and After Relaxation of Training Requirements.《COVID-19 大流行期间及培训要求放宽后美国临床医生开具丁丙诺啡管理阿片类药物使用障碍的豁免权变化》
JAMA Netw Open. 2022 May 2;5(5):e225996. doi: 10.1001/jamanetworkopen.2022.5996.
3
Characteristics and prescribing practices of clinicians recently waivered to prescribe buprenorphine for the treatment of opioid use disorder.最近获准开具丁丙诺啡用于治疗阿片类药物使用障碍的临床医生的特征和处方实践。
Addiction. 2019 Mar;114(3):471-482. doi: 10.1111/add.14436. Epub 2018 Oct 15.
4
Geographic and specialty distribution of US physicians trained to treat opioid use disorder.接受过治疗阿片类药物使用障碍培训的美国医生的地理分布和专业分布。
Ann Fam Med. 2015 Jan-Feb;13(1):23-6. doi: 10.1370/afm.1735.
5
Buprenorphine maintenance treatment in patients with opioid use disorder diagnosed with COVID-19.COVID-19 诊断为阿片类药物使用障碍的患者的丁丙诺啡维持治疗。
J Opioid Manag. 2020 Nov-Dec;16(6):405-407. doi: 10.5055/jom.2020.0598.
6
Rapid upscale of depot buprenorphine (CAM2038) in custodial settings during the early COVID-19 pandemic in New South Wales, Australia.在澳大利亚新南威尔士州新冠疫情早期，拘留场所中丁丙诺啡长效注射剂（CAM2038）的快速推广。
Addiction. 2021 Feb;116(2):426-427. doi: 10.1111/add.15244. Epub 2020 Sep 21.
7
Leveraging pharmacists to maintain and extend buprenorphine supply for opioid use disorder amid COVID-19 pandemic.利用药剂师在 COVID-19 大流行期间维持和扩大阿片类药物使用障碍的丁丙诺啡供应。
Am J Health Syst Pharm. 2021 Mar 18;78(7):613-618. doi: 10.1093/ajhp/zxab003.
8
Buprenorphine Opioid Treatment During the COVID-19 Pandemic.新冠疫情期间的丁丙诺啡阿片类药物治疗
JAMA Intern Med. 2021 Aug 1;181(8):1135. doi: 10.1001/jamainternmed.2021.0777.
9
Buprenorphine Opioid Treatment During the COVID-19 Pandemic-Reply.COVID-19大流行期间的丁丙诺啡阿片类药物治疗——回复
JAMA Intern Med. 2021 Aug 1;181(8):1135-1136. doi: 10.1001/jamainternmed.2021.0774.
10
Use of and Retention on Video, Telephone, and In-Person Buprenorphine Treatment for Opioid Use Disorder During the COVID-19 Pandemic.在 COVID-19 大流行期间，视频、电话和面对面使用丁丙诺啡治疗阿片类药物使用障碍的情况和保留率。
JAMA Netw Open. 2022 Oct 3;5(10):e2236298. doi: 10.1001/jamanetworkopen.2022.36298.

引用本文的文献

1
Trends in the Prescribing of Buprenorphine for Opioid Use Disorder, 2019-2023.2019 - 2023年用于阿片类物质使用障碍的丁丙诺啡处方趋势
Mayo Clin Proc Innov Qual Outcomes. 2024 May 24;8(3):308-320. doi: 10.1016/j.mayocpiqo.2024.04.004. eCollection 2024 Jun.
2
Growing importance of high-volume buprenorphine prescribers in OUD treatment: 2009-2018.阿片类物质使用障碍治疗中大量开处丁丙诺啡处方医生的重要性日益增加：2009-2018 年。
Drug Alcohol Depend. 2024 Jun 1;259:111290. doi: 10.1016/j.drugalcdep.2024.111290. Epub 2024 Apr 16.
3
Changes in Buprenorphine Prescribing in Community Health Centers.社区卫生中心丁丙诺啡处方的变化
JAMA Health Forum. 2024 Apr 5;5(4):e240634. doi: 10.1001/jamahealthforum.2024.0634.
4
A qualitative exploration of the use of telehealth for opioid treatment: Implications for nurse-managed care.一项关于远程医疗用于阿片类药物治疗的定性探索：对护士管理式医疗的启示。
J Clin Nurs. 2024 Jul;33(7):2707-2718. doi: 10.1111/jocn.17125. Epub 2024 Mar 18.
5
Perspectives on APRN prescribing of medications for opioid use disorder: Key barriers remain.关于 APRN 开具阿片类药物使用障碍治疗药物的观点：主要障碍仍然存在。
J Subst Use Addict Treat. 2024 Feb;157:209215. doi: 10.1016/j.josat.2023.209215. Epub 2023 Nov 18.
6
Impact of Stigma on Clinician Training for Opioid Use Disorder Care: A Qualitative Study in a Primary Care Learning Collaborative.耻辱感对阿片类药物使用障碍护理临床医生培训的影响：初级保健学习协作中的定性研究。
Ann Fam Med. 2023 Feb;21(Suppl 2):S31-S38. doi: 10.1370/afm.2920.
7
Eliminate the buprenorphine DEA X waiver: Justification using a policy analysis approach.取消丁丙诺啡 DEA X 豁免：使用政策分析方法的理由。
J Nurs Scholarsh. 2023 May;55(3):655-664. doi: 10.1111/jnu.12871. Epub 2023 Jan 9.

本文引用的文献

1
Assessment of State and Federal Health Policies for Opioid Use Disorder Treatment During the COVID-19 Pandemic and Beyond.评估新冠疫情期间及之后的州和联邦阿片类药物使用障碍治疗政策。
JAMA Health Forum. 2021 Nov;2(11):e213833. doi: 10.1001/jamahealthforum.2021.3833. Epub 2021 Nov 19.
2
Changes in US Clinician Waivers to Prescribe Buprenorphine Management for Opioid Use Disorder During the COVID-19 Pandemic and After Relaxation of Training Requirements.《COVID-19 大流行期间及培训要求放宽后美国临床医生开具丁丙诺啡管理阿片类药物使用障碍的豁免权变化》
JAMA Netw Open. 2022 May 2;5(5):e225996. doi: 10.1001/jamanetworkopen.2022.5996.
3
State Policies and Buprenorphine Prescribing by Nurse Practitioners and Physician Assistants.州政策与护士从业者和医师助理开具丁丙诺啡处方
Med Care Res Rev. 2022 Dec;79(6):789-797. doi: 10.1177/10775587221086489. Epub 2022 Apr 18.
4
Use of Medication for Opioid Use Disorder Among US Adolescents and Adults With Need for Opioid Treatment, 2019.2019 年美国需要阿片类药物治疗的青少年和成年人中，阿片类药物使用障碍药物治疗的使用情况。
JAMA Netw Open. 2022 Mar 1;5(3):e223821. doi: 10.1001/jamanetworkopen.2022.3821.
5
Medicaid participation among practitioners authorized to prescribe buprenorphine.获准开具丁丙诺啡的从业者的医疗补助参与情况。
J Subst Abuse Treat. 2022 Feb;133:108513. doi: 10.1016/j.jsat.2021.108513. Epub 2021 Jun 1.
6
Evaluating buprenorphine prescribing and opioid-related health outcomes following the expansion the buprenorphine waiver program.评估丁丙诺啡处方和阿片类药物相关健康结果后扩大丁丙诺啡豁免计划。
J Subst Abuse Treat. 2022 Jan;132:108452. doi: 10.1016/j.jsat.2021.108452. Epub 2021 Apr 30.
7
The Association Between Scope of Practice Regulations and Nurse Practitioner Prescribing of Buprenorphine After the 2016 Opioid Bill.《2016 年阿片类药物法案后实践范围法规与护士从业者开处丁丙诺啡处方的关联性》
Med Care Res Rev. 2022 Apr;79(2):290-298. doi: 10.1177/10775587211004311. Epub 2021 Apr 1.
8
Tracking the geographic distribution and growth of clinicians with a DEA waiver to prescribe buprenorphine to treat opioid use disorder.追踪具有 DEA 豁免权开具丁丙诺啡治疗阿片类药物使用障碍的临床医生的地理分布和增长情况。
J Rural Health. 2022 Jan;38(1):87-92. doi: 10.1111/jrh.12569. Epub 2021 Mar 18.
9
In Rural Areas, Buprenorphine Waiver Adoption Since 2017 Driven By Nurse Practitioners And Physician Assistants.自 2017 年以来，农村地区通过护士从业者和医师助理采用丁丙诺啡豁免疫。
Health Aff (Millwood). 2019 Dec;38(12):2048-2056. doi: 10.1377/hlthaff.2019.00859.
10
Prescribing Practices of Nurse Practitioners and Physician Assistants Waivered to Prescribe Buprenorphine and the Barriers They Experience Prescribing Buprenorphine.护士从业者和医师助理的处方实践，以及他们在开具丁丙诺啡处方时所经历的障碍。
J Rural Health. 2020 Mar;36(2):187-195. doi: 10.1111/jrh.12404. Epub 2019 Oct 25.

丁丙诺啡治疗：高级执业护士增加服务能力。

Buprenorphine Treatment: Advanced Practice Nurses Add Capacity.

机构信息

Joanne Spetz (

Laurie Hailer, QuantGal LLC, Fairfax, California.

出版信息

Health Aff (Millwood). 2022 Sep;41(9):1231-1237. doi: 10.1377/hlthaff.2022.00310.

DOI:10.1377/hlthaff.2022.00310
PMID:36067440
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC11062238/
Abstract

During the COVID-19 pandemic, there was slower growth in the number of new waivers authorizing clinicians to provide buprenorphine treatment for opioid use disorder. However, treatment capacity grew at a stable rate as a result of already authorized clinicians obtaining waivers for larger patient panels. Advanced practice nurses accounted for the largest portion of capacity growth during the pandemic.

摘要

在 COVID-19 大流行期间，新的授权临床医生为阿片类药物使用障碍提供丁丙诺啡治疗的豁免数量增长缓慢。然而，由于已经获得授权的临床医生为更大的患者群体获得了豁免，因此治疗能力以稳定的速度增长。在大流行期间，高级执业护士占能力增长的最大部分。